Literature DB >> 11666012

Relationship of calbindin D28K-immunoreactive cells and neuropathological changes in the hippocampal formation of Alzheimer's disease.

S Iritani1, K Niizato, P C Emson.   

Abstract

Previous studies have reported that calcium binding proteins, which have important functions in regulating the intracellular ion concentration, may influence the vulnerability of neurons in neurodegenerative disease. It has been observed that the neurons containing calbindin D28K (CB) may in certain circumstances be more resistant to excitotoxic and ischemic injury. In the present study the susceptibility of hippocampal neurons containing CB to develop NFT was studied, and the distribution of CB cells was compared with hippocampal plaque density in the Alzheimer's disease (AD) brain. Interestingly CB-positive hippocampal neurons did not contain tangles and could be seen next to degenerating tau-positive pyramidal cells. Comparison of the hippocampal plaque distribution with that of CB neurons showed that in general CB-positive neurons were found in areas with a low plaque burden. Further comparison of cases with differing degrees of severity indicated that CB-positive neurons were relatively preserved in cases with moderate plaque and tangle content but that in severe cases the CB-positive pyramidal cells were lost. These findings indicate that CB cells may be protected in the earlier stages of the disease but that this resistance ability is lost in the late stages of AD. The observation that CB-positive pyramidal cells do not accumulate NFT suggests that proteolysis of tau differs in CB-negative and CB-positive cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11666012     DOI: 10.1046/j.1440-1789.2001.00393.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  10 in total

Review 1.  Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease.

Authors:  Ilya Bezprozvanny; Mark P Mattson
Journal:  Trends Neurosci       Date:  2008-07-31       Impact factor: 13.837

2.  Calbindin-1 Expression in the Hippocampus following Neonatal Hypoxia-Ischemia and Therapeutic Hypothermia and Deficits in Spatial Memory.

Authors:  Janasha Goffigan-Holmes; Dafne Sanabria; Johana Diaz; Debra Flock; Raul Chavez-Valdez
Journal:  Dev Neurosci       Date:  2019-03-12       Impact factor: 2.984

3.  Age-related downregulation of the CaV3.1 T-type calcium channel as a mediator of amyloid beta production.

Authors:  Rachel A Rice; Nicole C Berchtold; Carl W Cotman; Kim N Green
Journal:  Neurobiol Aging       Date:  2013-10-30       Impact factor: 4.673

4.  Cerebrospinal Fluid Calbindin D Concentration as a Biomarker of Cerebellar Disease Progression in Niemann-Pick Type C1 Disease.

Authors:  Allison Bradbury; Jessica Bagel; Maureen Sampson; Nicole Farhat; Wenge Ding; Gary Swain; Maria Prociuk; Patricia O'Donnell; Kenneth Drobatz; Brittney Gurda; Christopher Wassif; Alan Remaley; Forbes Porter; Charles Vite
Journal:  J Pharmacol Exp Ther       Date:  2016-06-15       Impact factor: 4.402

5.  Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis.

Authors:  Rebecca Craig-Schapiro; Max Kuhn; Chengjie Xiong; Eve H Pickering; Jingxia Liu; Thomas P Misko; Richard J Perrin; Kelly R Bales; Holly Soares; Anne M Fagan; David M Holtzman
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

6.  Crucial role of calbindin-D28k in the pathogenesis of Alzheimer's disease mouse model.

Authors:  S-Y Kook; H Jeong; M J Kang; R Park; H J Shin; S-H Han; S M Son; H Song; S H Baik; M Moon; E C Yi; D Hwang; I Mook-Jung
Journal:  Cell Death Differ       Date:  2014-05-23       Impact factor: 15.828

7.  Neurogenesis, Neurodegeneration, Interneuron Vulnerability, and Amyloid-β in the Olfactory Bulb of APP/PS1 Mouse Model of Alzheimer's Disease.

Authors:  Carlos De la Rosa-Prieto; Daniel Saiz-Sanchez; Isabel Ubeda-Banon; Alicia Flores-Cuadrado; Alino Martinez-Marcos
Journal:  Front Neurosci       Date:  2016-05-30       Impact factor: 4.677

8.  Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.

Authors:  Antonio Cuadrado; Sebastian Kügler; Isabel Lastres-Becker
Journal:  Redox Biol       Date:  2017-11-06       Impact factor: 11.799

9.  Cell Type-Specific Human APP Transgene Expression by Hippocampal Interneurons in the Tg2576 Mouse Model of Alzheimer's Disease.

Authors:  Corinna Höfling; Emira Shehabi; Peer-Hendrik Kuhn; Stefan F Lichtenthaler; Maike Hartlage-Rübsamen; Steffen Roßner
Journal:  Front Neurosci       Date:  2019-02-22       Impact factor: 4.677

10.  Calbindin Deficits May Underlie Dissociable Effects of 5-HT6 and mGlu7 Antagonists on Glutamate and Cognition in a Dual-Hit Neurodevelopmental Model for Schizophrenia.

Authors:  Sinead E Shortall; Angus M Brown; Eliot Newton-Mann; Erin Dawe-Lane; Chanelle Evans; Maxine Fowler; Madeleine V King
Journal:  Mol Neurobiol       Date:  2020-06-12       Impact factor: 5.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.